These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1251 related articles for article (PubMed ID: 18199160)

  • 21. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
    Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
    Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
    Kambara T; Simms LA; Whitehall VL; Spring KJ; Wynter CV; Walsh MD; Barker MA; Arnold S; McGivern A; Matsubara N; Tanaka N; Higuchi T; Young J; Jass JR; Leggett BA
    Gut; 2004 Aug; 53(8):1137-44. PubMed ID: 15247181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
    Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
    Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
    Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
    Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
    Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
    Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.
    Kim JH; Shin SH; Kwon HJ; Cho NY; Kang GH
    Virchows Arch; 2009 Dec; 455(6):485-94. PubMed ID: 19911194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):585-92. PubMed ID: 17239930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
    Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
    Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.
    Tanaka N; Huttenhower C; Nosho K; Baba Y; Shima K; Quackenbush J; Haigis KM; Giovannucci E; Fuchs CS; Ogino S
    Am J Pathol; 2010 Dec; 177(6):2731-40. PubMed ID: 21037082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.
    Ferracin M; Gafà R; Miotto E; Veronese A; Pultrone C; Sabbioni S; Lanza G; Negrini M
    J Pathol; 2008 Apr; 214(5):594-602. PubMed ID: 18241079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.